Belite Bio (BLTE) Depreciation and Depletion (2024 - 2025)

Belite Bio (BLTE) posted quarterly Depreciation and Depletion of $45000.0 for Q4 2025, up 4.65% year-over-year from $43000.0 in Q4 2024, and up 4.65% on a QoQ basis from $43000.0 in Q4 2024.

Belite Bio (BLTE) Depreciation and Depletion (2024 - 2025) Analysis & Trends

Belite Bio (BLTE) has reported Depreciation and Depletion for 2 consecutive years, with $45000.0 the latest figure, recorded in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Depletion (Qtr)
1 Genmab A 276,399.99 Bn 276,398.47 Bn 831.00 Mn 16.00 Mn
2 Akari Therapeutics 1,217.26 Bn 1,217.26 Bn - -
3 BeOne Medicines 419.38 Bn 414.59 Bn 1.35 Bn 39.39 Mn
4 Vertex Pharmaceuticals 126.54 Bn 119.30 Bn 2.59 Bn -
5 Pharming 110.17 Bn 110.12 Bn 65.80 Mn -
6 Regeneron Pharmaceuticals 64.97 Bn 56.22 Bn 3.31 Bn -
7 Argenx Se 56.44 Bn 56.44 Bn 1.18 Bn -
8 Alnylam Pharmaceuticals 40.09 Bn 37.08 Bn 959.66 Mn -
9 Revolution Medicines 37.15 Bn 37.15 Bn - 2.20 Mn
10 Belite Bio 96.77 Mn 96.77 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 45,000.00
Dec 31, 2025 45,000.00
Dec 31, 2024 43,000.00
Dec 31, 2024 43,000.00